RELATIVE LOW FLOW EXTRA CORPOREAL CO2-REMOVAL IN ARDS PATIENTS: A PILOT STUDY by H Peperstraete et al.
POSTER PRESENTATION Open Access
Relative low flow extra corporeal CO2-removal in
ards patients: a pilot study
H Peperstraete1*, S Eloot2, P Depuydt1, C Roosens1, F De Somer3, E Hoste1
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Introduction
Mechanical ventilation (MV) of patients with Acute
Respiratory Distress Syndrome (ARDS) should be per-
formed with a lung protective strategy, since this is asso-
ciated with better clinical outcomes. Lung protective
MV contains the lowering of the plateau pressure
(PPLAT) and the tidal volume (VT). Physician’s choice for
lung protective MV can be hindered by the consequence
of decreased CO2 clearance, i.e. respiratory acidosis.
Veno-venous extracorporeal CO2-removal (ECCO2-R)
is a recent therapy allowing extracorporeal CO2 clear-
ance and normalisation of pH.
Objectives
The aim of this pilot study was to evaluate whether
ECCO2-R using relative low blood flow was able to treat
respiratory acidosis in ARDS patients treated with lung
protective MV, so that further reduction of PPLAT and
VT was feasible.
Methods
This is a single centre trial in which patients who met
the Berlin definition of ARDS with a PaO2/FiO2 <
150mmHg and who had respiratory acidosis were
included. The first 2 hours of therapy blood flow was
300ml/min, after which it was increased to 400ml/min.
During the ECCO2-R we aimed at lowering PPLAT and
VT. For every patient we used the Abylcap
® device
(Bellco, Italy) with either the Lynda® machine (8 patients)
or the Amplya™ (1 patient). Every patient was hepari-
nized to prevent clotting of the circuit and oxygenator.
During the complete study period, ventilator settings and
results of blood gases were recorded. Data are reported
as median [interquartile range] or n (%).
Results
We included 9 patients, 4 female, with a median age of
50 y [22.8, 66.5]. All patients showed a decrease of
pCO2 after 2 hours of treatment with median reduction
of 28.2% [11.6, 31.0; p = 0.008]; five patients (56%) had
a decrease in pCO2 of more than 20%. The median
reduction in PPLAT after 5 days (D5) of treatment was
8.5cmH2O (5.3, 12.5; p = 0.012). Median reduction in
VT at D5 was 1.52ml/kg predicted body weight (0.65,
1.85; p = 0.017). In all patients pH could be corrected to
normal range values with an increase of median pH
from 7.17 (7.11, 7.21) at inclusion to 7.42 (7.40 ,7.44)
(p = 0.012) at D5. ECCO2-R was hemodynamically well
tolerated. Three patients needed a blood transfusion
because of bleeding. Two patients needed a circuit
renewal earlier than scheduled because of clotting of the
circuit or oxygenator, both patients were treated with
the Lynda® machine.
Conclusions
In patients with moderate ARDS, veno-venous ECCO2-R
using relative low blood flow is a promising extracorpor-
eal technique allowing removal of CO2, thus allowing
MV with lower PPLAT and VT. An explanation for the
inter-patient variation in efficiency of CO2 removal
could not be found in our patient cohort.
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